Headlines

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

Published by Global Banking & Finance Review

Posted on October 16, 2025

1 min read

· Last updated: January 21, 2026

Add as preferred source on Google
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal

Hansoh Pharma Enters $1.45 Billion Licensing Deal with Roche for Cancer Drug

Overview of the Licensing Agreement

(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors. 

Details of the Agreement

(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

  • Hansoh Pharma signs a $1.45 billion deal with Roche.
  • The agreement focuses on a colorectal cancer drug.
  • The drug targets colorectal cancer and other solid tumors.
  • This deal enhances Hansoh's oncology portfolio.
  • Roche's subsidiary is involved in the agreement.

Frequently Asked Questions

What is colorectal cancer?
Colorectal cancer is a type of cancer that starts in the colon or rectum. It is one of the most common types of cancer and can be influenced by factors like diet and genetics.
What is a subsidiary?
A subsidiary is a company that is completely or partially owned and controlled by another company, known as the parent company.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category